Corcept Therapeutics Inc. operates primarily in the United States, focusing its research and commercialization efforts on selective cortisol modulators. The company's flagship product, Korlym (mifepristone), was approved by the FDA in 2012 for the treatment of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome. In addition to its endocrinology franchise, Corcept is expanding into oncology, recently securing FDA approval for Lifyorli (relacorilant) to treat platinum-resistant ovarian cancer. The company's clinical pipeline includes over 1,000 proprietary compounds targeting conditions such as amyotrophic lateral sclerosis (ALS), metabolic dysfunction-associated steatohepatitis (MASH), and various solid tumors. Corcept operates as a single reportable segment dedicated to the discovery, development, and commercialization of pharmaceutical products.
